Lanza F, Panagides J, Salom I L
J Rheumatol. 1986 Apr;13(2):299-303.
Forty-eight normal men participated in a 14-day, single blind, single center, multiple dose study of gastric irritation using endoscopy. Subjects were randomly assigned to one of 4 treatment groups after a one week lead-in period, as follows: etodolac 200 mg BID, 400 mg BID, 600 mg BID, or aspirin 975 mg QID. Etodolac at all dose levels produced significantly (p less than or equal to 0.0001) less gastrointestinal irritation than aspirin as assessed by endoscopic examination of the gastric and duodenal sites. There were no significant differences among the 3 etodolac groups.
48名正常男性参与了一项为期14天的单盲、单中心、多剂量的内镜下胃刺激研究。在为期一周的导入期后，受试者被随机分配到4个治疗组之一，如下：依托度酸200毫克，每日两次；400毫克，每日两次；600毫克，每日两次；或阿司匹林975毫克，每日四次。通过对胃和十二指肠部位的内镜检查评估，所有剂量水平的依托度酸产生的胃肠道刺激均显著低于阿司匹林（p小于或等于0.0001）。3个依托度酸组之间无显著差异。
